We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Privacy Terms and Cookie Policy
Balanced Reporting. Trusted Insights.
Tuesday, May 17, 2022
The Supreme Court should deny a petition from Monsanto seeking review of an appeals court decision that upheld a $25 million verdict against the company for failing to adequately warn a consumer about the health risks of Roundup exposure.
A “substantial reduction in production rates” at a manufacturing plant that supplies one of the raw ingredients needed to make glyphosate herbicide will affect Bayer’s ability to deliver products containing the chemical, the company says.
Three federal appeals court judges are wrestling with the question of whether to vacate the registration of glyphosate, the active ingredient in Roundup.
The American Farm Bureau Federation’s annual meeting is underway in Atlanta, and the president of the nation’s largest ag group is keeping the pressure on the Biden administration to deal with supply chain disruptions and remove barriers to U.S. ag exports.
German law firm has filed lawsuits against Bayer in a Cologne regional court on behalf of investors who are seeking about $2.48 billion in compensation in connection with Bayer’s $63 billion purchase of Monsanto.
Bayer has filed a petition with the Supreme Court requesting the review of a Ninth Circuit Court of Appeals decision that upheld a $25 million award to a California man who alleges exposure to Roundup caused his Non-Hodgkin lymphoma.
In an attempt to get out from under the cloud of current Roundup-related litigation, Bayer announced Thursday it would stop using glyphosate in lawn and garden formulations in the U.S. starting in 2023.
A California Superior Court Judge has ruled that a California woman’s claim that Bayer failed to warn her of the dangers of using Roundup is pre-empted by federal law, an argument Bayer has so far failed to make successfully in the federal courts.
Bayer scientists on Tuesday discussed a June draft report from regulators in four European Union countries that concluded the chemical meets the EU approval criteria for renewed registration. They also underscored the company's belief that the product offers benefits of effectiveness not available in its alternatives.